Submit exa-cel regulatory applications for SCD and TDT in Europe and the UK
Delivered by the deadline
AI-confirmed · human review in progress Independent AI checks agreed on primary SEC or regulator evidence. Records are now being reviewed by hand, starting with those our customers order.
- Announced
- 4 Aug 2022
- Due
- 31 Dec 2022
- Deadline
- Met
- Late
- Not met
- Today
What the company said
“Vertex has completed discussions with the EMA and the MHRA... and is on track to submit for regulatory approvals of exa-cel for SCD and TDT in Europe and the UK by the end of 2022.”
What we found
Evidence strength A What the grades mean
Filings state Vertex completed EMA and MHRA submissions for exa-cel for SCD and TDT in the fourth quarter of 2022, specifically December 2022, before the deadline.
-
A Vertex Pharmaceuticals 8-K filed 2023-02-07
“In December 2022, Vertex completed regulatory submissions for exa-cel with the EMA and MHRA in the EU and the U.K., respectively.” ✓ confirmed on the page
-
A Vertex Pharmaceuticals 10-K filed 2023-02-10
“In the fourth quarter of 2022, we completed regulatory submissions to the European Medicines Agency (“EMA”) and the MHRA for exa-cel for SCD and TDT, and both the EMA and the MHRA have validated the marketing authorization application.” ✓ confirmed on the page
Market reaction: the shares moved -3.7% against the S&P 500 over the three sessions around the disclosure (6 Feb 2023 to 9 Feb 2023). What this measures
Checked 10 Oct 2026.
Commitment DNA
The structured record of this commitment. Fields the company did not state are left blank rather than guessed.
- Event type
- Regulatory other
- Indicative materiality
- Medium rules
- Action
- Submit
- Deliverable
- Exa-cel regulatory submissions for SCD and TDT
- Where
- Europe and the UK
- Language
- Firm (“will”, “on track to”)
- In the company’s control
- High
- Specificity
- High
- Depends on
- Partner
How this entry was checked
- Commitment recordedThe company's words were matched word for word against the filing.
- First checkAn AI model, Claude (Anthropic), read the company's later filings and recorded the outcome with a quoted passage.
- Second check: agreesA different AI model, Gemini (Google), re-read the evidence without being told the outcome and reached the same answer.
Confirmed. This outcome counts towards the company's Kept Score. How verification works
Are you Vertex Pharmaceuticals? You can publish an official statement next to this entry, free. Add a statement.
Is something here wrong or out of date? Companies and readers can ask us to check it. Please bring a link to a public source.
Report an error in this entry Reference: KI-C-2022-VRTX-006517 · Corrections policy